Pediatric Persistent Asthma. Predominantly allergic asthma
Conditions
Interventions
Intervention 1: First group: Patients of one group will receive 100 micrograms of inhaled beclomethasone three times a day with 5 mg of montelukast tablets daily. Intervention 2: Second group: Patient
Treatment - Drugs
First group: Patients of one group will receive 100 micrograms of inhaled beclomethasone three times a day with 5 mg of montelukast tablets daily.
Second group: Patients only will receive 100 micrograms of inhaled beclomethasone three times a day.
Sponsors
Vice- Chancellor for Research Technology Affairs, Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 10 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Pediatrics aged 6 to 10 years; Pediatrics with persistent asthma symptoms; referred to the Center during the study; Exclusion criteria: Pediatrics with lung infections; Pediatrics any underlying illness such as simultaneous cardiac disease; Antihistamine use; Having any illness; Taking other medications;
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Go to school. Timepoint: At the end of the treatment. Method of measurement: Take report from parent and completion in the questionnaire.;Night sleep quality (sleep deprivation). Timepoint: At the end of the treatment. Method of measurement: Take report from parent and completion in the questionnaire. | — |
Primary
| Measure | Time frame |
|---|---|
| FEV1. Timepoint: Before and 3 months after treatment. Method of measurement: With spirometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Iraj Mohammadzadeh
Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of
Outcome results
None listed